Abstract
Aims. The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown. Methods and study design. Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated. Results. Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity. Conclusions. Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.
| Original language | English |
|---|---|
| Pages (from-to) | 605-611 |
| Number of pages | 7 |
| Journal | Tumori |
| Volume | 100 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 1 2014 |
Fingerprint
Keywords
- Trastuzumab after lapatinib
- Trastuzumab and lapatinib
- Treatment with trastuzumab beyond progression
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer : A single-institution experience. / Carli, Paolo; Militello, Loredana; Miolo, Gian Maria; Quitadamo, Daniela; Lombardi, Davide; Torrisi, Elena; Scalone, Simona; Crivellari, Diana; Spazzapan, Simon.
In: Tumori, Vol. 100, No. 6, 01.11.2014, p. 605-611.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer
T2 - A single-institution experience
AU - Carli, Paolo
AU - Militello, Loredana
AU - Miolo, Gian Maria
AU - Quitadamo, Daniela
AU - Lombardi, Davide
AU - Torrisi, Elena
AU - Scalone, Simona
AU - Crivellari, Diana
AU - Spazzapan, Simon
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Aims. The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown. Methods and study design. Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated. Results. Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity. Conclusions. Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.
AB - Aims. The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown. Methods and study design. Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated. Results. Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity. Conclusions. Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.
KW - Trastuzumab after lapatinib
KW - Trastuzumab and lapatinib
KW - Treatment with trastuzumab beyond progression
UR - http://www.scopus.com/inward/record.url?scp=84923289468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923289468&partnerID=8YFLogxK
U2 - 10.1700/1778.19260
DO - 10.1700/1778.19260
M3 - Article
C2 - 25688493
AN - SCOPUS:84923289468
VL - 100
SP - 605
EP - 611
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 6
ER -